ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
81,295
0,00%
Bitcoin
67 583,50
-0,21%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. 180 Life Sciences Corporation (ATNF)

  7. 180 Life Sciences Corporation (ATNF) Actualités

ATNF

180 Life Sciences (ATNF)

180 Life Sciences Corporation
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ATNF
DateHeureSourceTitreSymboleSociété
14/03/202413h30GlobeNewswire Inc.180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:ATNF180 Life Sciences Corporation
11/03/202412h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATNF180 Life Sciences Corporation
28/02/202412h42Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ATNF180 Life Sciences Corporation
26/02/202413h00GlobeNewswire Inc.180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance PlanNASDAQ:ATNF180 Life Sciences Corporation
31/01/202423h29Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:ATNF180 Life Sciences Corporation
29/12/202300h42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATNF180 Life Sciences Corporation
27/12/202322h15Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ATNF180 Life Sciences Corporation
26/12/202322h15Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ATNF180 Life Sciences Corporation
14/12/202322h30Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ATNF180 Life Sciences Corporation
04/12/202315h00GlobeNewswire Inc.180 Life Sciences Engages Financial Advisor to Explore Strategic AlternativesNASDAQ:ATNF180 Life Sciences Corporation
28/11/202315h00GlobeNewswire Inc.180 Life Sciences Announces Review of Strategic AlternativesNASDAQ:ATNF180 Life Sciences Corporation
09/11/202323h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ATNF180 Life Sciences Corporation
30/08/202322h56Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ATNF180 Life Sciences Corporation
14/08/202323h00Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:ATNF180 Life Sciences Corporation
14/08/202322h29GlobeNewswire Inc.180 Life Sciences Corp. Announces Closing of $3 Million Public OfferingNASDAQ:ATNF180 Life Sciences Corporation
10/08/202314h46GlobeNewswire Inc.180 Life Sciences Corp. Announces Pricing of $3 Million Public OfferingNASDAQ:ATNF180 Life Sciences Corporation
10/08/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ATNF180 Life Sciences Corporation
07/08/202315h00GlobeNewswire Inc.180 Life Sciences Announces an Agreement for a Clinical Pharmacology Study Testing a New Formulation of CBD for Enhanced Oral UptakeNASDAQ:ATNF180 Life Sciences Corporation
03/08/202314h00GlobeNewswire Inc.180 Life Sciences Provides Update on Regulatory Approval Process in the UK and US for Dupuytren’s Disease Treatment; Continues Consultations with the UK MHRA and Initiates a Type C Meeting Request With the US FDANASDAQ:ATNF180 Life Sciences Corporation
31/07/202314h00GlobeNewswire Inc.180 Life Sciences Corp. Announces the Filing of a Provisional Patent Describing the Combination of CBD With GLP-1 Agonists to Suppress AppetiteNASDAQ:ATNF180 Life Sciences Corporation
25/07/202323h02Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:ATNF180 Life Sciences Corporation
02/06/202314h01Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ATNF180 Life Sciences Corporation
15/05/202323h07Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:ATNF180 Life Sciences Corporation
15/05/202322h25Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ATNF180 Life Sciences Corporation
15/05/202312h36Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:ATNF180 Life Sciences Corporation
10/05/202312h07Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:ATNF180 Life Sciences Corporation
28/04/202323h29Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ATNF180 Life Sciences Corporation
28/04/202323h27Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:ATNF180 Life Sciences Corporation
14/04/202323h00Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:ATNF180 Life Sciences Corporation
10/04/202322h30GlobeNewswire Inc.180 Life Sciences Corp. Announces Closing of $3 Million Registered Direct Offering and Concurrent Private PlacementNASDAQ:ATNF180 Life Sciences Corporation
 Showing the most relevant articles for your search:NASDAQ:ATNF

Dernières Valeurs Consultées

COIN
BTCUSD
Bitcoin
EU
RNO
Renault
EU
ML
Michelin
FTSE
UKX
FTSE 100
USI
USTECH100
US Tech 100
EU
SGO
Cie de SaintGobain
NASDAQ
MSFT
Microsoft
EU
VIV
Vivendi
EU
PX4
SBF 120
EU
EN
Bouygues
EU
BN
Danone
NYSE
NKE
Nike
NASDAQ
GOOGL
Alphabet
EU
HO
Thales
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés